36945-03-6|Lergotrile|2-((6aR,9S,10aR)-5-chloro-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)acetonitrile|-范德生物科技公司

Lergotrile

NMR下载 COA and HPLC MSDS下载
names：
2-((6aR,9S,10aR)-5-chloro-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)acetonitrile
CAS号：
36945-03-6
MDL Number：
MF(分子式)： C17H18ClN3 MW(分子量)： 299.8
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Lergotrile
英文别名	Lergotrile; 79907; LY 79907; LY-79907; LY79907;
CAS号	36945-03-6
Inchi	InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1
InchiKey	JKAHWGPTNVUTNB-IXPVHAAZSA-N
分子式 Formula	C17H18ClN3
分子量 Molecular Weight	299.8
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Lergotrile(CAS:36945-03-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Lergotrile is an enzyme Inhibitor (Prolactin).
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Cunningham KA, Callahan PM, Appel JB. Discriminative stimulus properties of lergotrile. J Pharmacol Exp Ther. 1984 Jul;230(1):47-52. PubMed PMID: 6146709.

[2]Fuller RW, Perry KW. Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain. J Neural Transm. 1978;42(1):23-35. PubMed PMID: 641542.

[3] Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M. Lergotrile in Parkinson disease: further studies. Neurology. 1979 Feb;29(2):267-72. PubMed PMID: 34808.

[4] Schmidt MJ. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate. Eur J Pharmacol. 1979 Oct 26;59(1-2):95-101. PubMed PMID: 41730.

[5] Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB. Comparison between lergotrile and bromocriptine in parkinsonism. Ann Neurol. 1978 Apr;3(4):319-24. PubMed PMID: 666273.

6: Rubin A, Lemberger L, Dhahir P, Warrick P, Crabtree RE, Obermeyer BD, Wolen RL, Rowe H. Physiologic disposition of lergotrile. Clin Pharmacol Ther. 1978 Mar;23(3):272-80. PubMed PMID: 627132.7: Lew JY, Hata F, Ohashi T, Goldstein M. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors. J Neural Transm. 1977;41(2-3):109-21. PubMed PMID: 21229.8: Barrett RJ, Lokhandwala MF. Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile. J Pharmacol Exp Ther. 1981 Jun;217(3):660-5. PubMed PMID: 6112262.9: Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M. Treatment of Parkinson's disease with lergotrile mesylate. JAMA. 1977 Nov 28;238(22):2380-2. PubMed PMID: 335094.10: Bergmann F. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile. Isr J Med Sci. 1982 Jan;18(1):177-82. PubMed PMID: 6121772.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开